Astrazeneca

FromAstraZeneca ([email protected])
Sent withMailchimp
Subject (46)FDA ODAC vote on camizestrant in breast cancer
Preheader (131)Update on FDA Advisory Committee vote on camizestrant in combination with a CDK4/6 inhibitor for advanced HR-positive breast cancer
Typography
Arial
Colors
Text Analysis
Body Words166
Subject Words8
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images6
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px806 px
X-Spam Score-0.1
Preheader OptimizedNo
Timing
Day of WeekThursday
TimeEvening

FDA ODAC vote on camizestrant in breast cancer

Update on FDA Advisory Committee vote on camizestrant in combination with a CDK4/6 inhibitor for advanced HR-positive breast cancer
FDA ODAC vote on camizestrant in breast cancer